X-linked ichthyosis: increased blood cholesterol sulfate and electrophoretic mobility of low-density lipoprotein

Science ◽  
1981 ◽  
Vol 214 (4521) ◽  
pp. 659-660 ◽  
Author(s):  
E. Epstein ◽  
R. Krauss ◽  
C. Shackleton
Keyword(s):  
Electrophoretic Mobility ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Blood Cholesterol ◽  
Low Density ◽  
Cholesterol Sulfate

scholarly journals Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease

2020 ◽  
Vol 2020 (3) ◽  
Author(s):  
Parth N Patel ◽  
Robert P Giugliano
Keyword(s):  
Cardiovascular Disease ◽  
Secondary Prevention ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Blood Cholesterol ◽  
Atherosclerotic Cardiovascular Disease ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Lowering Therapy

Atherosclerotic cardiovascular disease (ASCVD) is highly prevalent and a major contributor to morbidity and mortality worldwide. Elevated blood cholesterol is a key driver of risk for atherosclerotic events, and patients with established ASCVD comprise a specific high-risk population in which low-density lipoprotein cholesterol (LDL-C) lowering therapy is strongly endorsed by multiple guidelines. An increasing number of medications across several pharmacologic classes are available today in clinical practice. Therefore, guidance on the appropriate use of these interventions is necessary for cost-effective solutions to managing residual atherothrombotic risk. In this review we summarize the key evidence supporting LDL-C lowering as described in the most recent 2018 multi-society Blood Cholesterol Guidelines, and provide a framework for optimizing LDL-C lowering therapy in secondary prevention populations.

scholarly journals Cynanchum wilfordii Etanolic Extract Controls Blood Cholesterol: A Double-blind, Randomized, Placebo-Controlled, Parallel Trial

Nutrients ◽  
2019 ◽  
Vol 11 (4) ◽  
pp. 836 ◽  
Author(s):  
Youn ◽  
Ham ◽  
Yoon ◽  
Choi ◽  
Lee ◽  
...  
Keyword(s):  
Total Cholesterol ◽  
Low Dose ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Ethanolic Extract ◽  
Blood Cholesterol ◽  
High Dose ◽  
Low Density ◽  
Double Blind ◽  
Cynanchum Wilfordii

We evaluated the effects of Cynanchum wilfordii (CW) ethanolic extract on blood cholesterol levels in adults with high low-density lipoprotein cholesterol (LDL-C) levels. In a double-blind, randomized, placebo-controlled, parallel trial, 84 subjects were recruited. Participants were randomly divided into two groups with a low-dose (300 mg/d) or high-dose (600 mg/d) of CW. Levels of very low-density lipoprotein (p = 0.022) and triglycerides (p = 0.022) were significantly lower in the low-dose CW group than in the placebo group after 8 weeks. In a subgroup of participants with LDL-C≥ 150 mg/dL (n = 33), there was a significant decrease in total cholesterol (low-dose, p = 0.012; high-dose, p = 0.021), apolipoprotein B (low-dose, p = 0.022; high-dose, p = 0.016), and cholesteryl ester transfer protein (low-dose, p = 0.037; high-dose, p = 0.016) after 8 weeks of CW. The correlation between changes in total cholesterol and baseline LDL-C levels was significant in the groups that received both doses of CW (low-dose, p = 0.010; high-dose, p = 0.015). These results show that the CW ethanolic extract can regulate blood cholesterol in subjects with LDL-C≥ 150 mg/dL.

Electrophoretic mobility in agarose of very low density lipoprotein subfractions in type III hyperlipoproteinaemia

1977 ◽  
Vol 75 (3) ◽  
pp. 487-490 ◽  
Author(s):  
Fiona C. Ballantyne ◽  
Dorothy K. Bedford ◽  
David Ballantyne ◽  
Jane L.H.C. Third ◽  
Peter Stromberg ◽  
...  
Keyword(s):  
Electrophoretic Mobility ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Very Low Density Lipoprotein ◽  
Low Density ◽  
Lipoprotein Subfractions ◽  
Type Iii

scholarly journals Evaluation of the Effects ofPinus koraiensisNeedle Extracts on Serum Lipid and Oxidative Stress in Adults with Borderline Dyslipidemia: A Randomized, Double-Blind, and Placebo-Controlled Clinical Trial

2016 ◽  
Vol 2016 ◽  
pp. 1-6
Author(s):  
Hansongyi Lee ◽  
Hyerang Kim ◽  
Ryowon Choue ◽  
Hyunjung Lim
Keyword(s):  
Oxidative Stress ◽  
Blood Pressure ◽  
Superoxide Dismutase ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Blood Cholesterol ◽  
Low Density ◽  
Vldl Cholesterol ◽  
Before And After ◽  
And Oxidative Stress

Background.Dyslipidemia has been well-known as a common metabolic disorder contributing to cardiovascular disease. The aim of this study was to evaluate the effect of thePinus koraiensisneedle extracts (PKE) on the blood cholesterol and oxidative stress.Method.We conducted a 12-week randomized, double-blinded controlled trial to examine the effect of PKE on blood lipid profiles in adults with borderline dyslipidemia. Thirty-three eligible persons were recruited and randomly assigned into PKE (n=20) and placebo groups (n=13). Serum lipids including total cholesterol, low-density lipoprotein- (LDL-) cholesterol, high-density lipoprotein- (HDL-) cholesterol, very low-density lipoprotein- (VLDL-) cholesterol, and triglyceride were measured before and after trial. Serum insulin, glucose, and antioxidant indicators were also analyzed before and after trial and anthropometry and blood pressure were measured every 4 weeks.Results.After 12 weeks, PKE statically significant decreases in systolic blood pressure (p<0.05) and waist circumference (p<0.05) were observed. Also, VLDL-cholesterol significantly decreased (from24.4±10.0 mg/dL at baseline to18.4±4.1 mg/dL after 12 weeks) (p<0.05) and superoxide dismutase (SOD) increased (6.12±0.41 U/mL to9.06±0.62 U/mL) (p<0.01) in PKE group. However, after adjustment with WC, VLDL-cholesterol was not significant between groups (p=0.095) and while SOD remained significant between groups (p=0.013).Conclusion.The results show that PKE was effective in improving the superoxide dismutase in the individuals with borderline dyslipidemia.

scholarly journals NON-PHARMACOLOGICAL THERAPY OF HYPERLIPIDAEMIA

2003 ◽  
Vol 41 (142) ◽  
pp. 356-360
Author(s):  
Urgra Narayan Pathak ◽  
D L Gurubacharya
Keyword(s):  
National Cholesterol Education Program ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Pharmacological Therapy ◽  
Blood Cholesterol ◽  
Low Density ◽  
First Line ◽  
Factors Associated

Hyperlipidaemia is one of the major contributors to atherosclerosis and CoronaryHeart Disease (CHD) in our society. Numerous clinical and epidemiological studieshave shown repeatedly that an elevated blood cholesterol level is one of the majormodifiable risk factors associated with the development of CHD. In particular, thesestudies have demonstrated that low- density lipoprotein (LDL) cholesterol is theprimary lipoprotein mediating atherosclerosis. Non-pharmacological therapy especiallydietary therapy and exercise remains the first line of treatment in hyperlipidaemia,with pharmacotherapy reserved for use in patients at high risk of coronary heartdisease or patients who do not respond to non-pharmacological therapyKey Words: Hyperlipidaemia, LDL Cholesterol, HDL Cholesterol, coronary HeartDisease (CHD), Atherosclerosis, National Cholesterol Education Program (NCEP)

scholarly journals IDOL G51S Variant Is Associated With High Blood Cholesterol and Increases Low-Density Lipoprotein Receptor Degradation

2019 ◽  
Vol 39 (12) ◽  
pp. 2468-2479 ◽  
Author(s):  
Dilare Adi ◽  
Xiao-Yi Lu ◽  
Zhen-Yan Fu ◽  
Jian Wei ◽  
Gulinaer Baituola ◽  
...  
Keyword(s):  
Low Density Lipoprotein ◽  
Cohort Analysis ◽  
Ldl Receptor ◽  
Density Lipoprotein ◽  
Serum Levels ◽  
Blood Cholesterol ◽  
Low Density ◽  
Interacting Protein ◽  
Density Lipoprotein Receptor ◽  
High Level

Objective: A high level of LDL-C (low-density lipoprotein cholesterol) is a major risk factor for cardiovascular disease. The E3 ubiquitin ligase named IDOL (inducible degrader of the LDLR [LDL receptor]; also known as MYLIP [myosin regulatory light chain interacting protein]) mediates degradation of LDLR through ubiquitinating its C-terminal tail. But the expression profile of IDOL differs greatly in the livers of mice and humans. Whether IDOL is able to regulate LDL-C levels in humans remains to be determined. Approach and Results: By using whole-exome sequencing, we identified a nonsynonymous variant rs149696224 in the IDOL gene that causes a G51S (Gly-to-Ser substitution at the amino acid site 51) from a Chinese Uygur family. Large cohort analysis revealed IDOL G51S carriers (+/G51S) displayed significantly higher LDL-C levels. Mechanistically, the G51S mutation stabilized IDOL protein by inhibiting its dimerization and preventing self-ubiquitination and subsequent proteasomal degradation. IDOL(G51S) exhibited a stronger ability to promote ubiquitination and degradation of LDLR. Adeno-associated virus-mediated expression of IDOL(G51S) in mouse liver decreased hepatic LDLR and increased serum levels of LDL-C, total cholesterol, and triglyceride. Conclusions: Our study demonstrates that IDOL(G51S) is a gain-of-function variant responsible for high LDL-C in both humans and mice. These results suggest that IDOL is a key player regulating cholesterol level in humans.

scholarly journals Cardio-protective properties of Momordica charantia in Albino Rats

2013 ◽  
Vol 12 (3) ◽  
pp. 291-297
Author(s):  
Ojulari Lekan Sheriff ◽  
FA Yusuf
Keyword(s):  
Plant Extract ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Momordica Charantia ◽  
Blood Cholesterol ◽  
Control Group ◽  
Albino Rats ◽  
Low Density ◽  
Protective Properties ◽  
Experimental Group

Momordica charantia, commonly known as bitter gourd, is used as a vegetable by the Asian community in Africa. It is frequently used as an anti-diabetic herb for the management of disease in the Ayurvedic system of Medicine. This present study was aimed at evaluating possible cardio-protective properties of M. charantia by determining its effect on blood cholesterol levels in albino rats. The study involved 25 rats and they were divided into 5 groups each comprising of 5 rats. The aqueous extract of M. Charantia was administered orally with syringes and cannula to 4 groups at different doses (80mg/kg, 100mg/kg, 120mg/kg and 140mg/kg body weights per day, respectively) and the last group served as the control and were given drug vehicle (normal saline) only. After two weeks of administration, the 25 rats were sacrificed and blood samples were collected and assayed for total blood cholesterol, triglyceride, highdensity lipoprotein and low-density lipoprotein levels. Results indicated that M. charantia plant extract increased significantly (P<0.05) the low density lipoprotein levels in the experimental group B (100mg/kg), and significantly reduced low density lipoprotein levels (P<0.05) in the experimental group A (80mg/kg), when compared to the control group. This study showed that M. charantia plant extract has cardio-protective properties by its dose-dependent effects on blood cholesterol. Bangladesh Journal of Medical Science Vol. 12 No. 03 July ’13 Page 291-297 DOI: http://dx.doi.org/10.3329/bjms.v12i3.15428

Sign in / Sign up

Export Citation Format

Share Document